title: Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
abstract: Gastroesophageal reflux disease is the most common upper gastroenterology disorder in the US. It is associated with a variety of complications and significantly impacts quality of life. Proton pump inhibitors are the most effective treatment. Dexlansoprazole modified release (MR) is a proton pump inhibitor that employs a novel release formulation that prolongs its absorption and allows for more flexibility in dosing. Dexlansoprazole MR can be dosed without regard to food intake or time of day, and once-daily dosing may replace twice-daily dosing of other agents. Dexlansoprazole MR is effective for healing and maintenance of erosive esophagitis, and for the treatment of nonerosive disease, including nocturnal gastroesophageal reflux disease. Dexlansoprazole MR is safe and well tolerated, and can improve quality of life.
authors.affiliation: Department of Medicine, Mount Sinai Beth Israel/Icahn School of Medicine.
authors.forename: Joseph
authors.initials: J
authors.lastname: Mermelstein
authors.affiliation: Department of Psychiatry, New York Presbyterian Hospital/Weill Cornell Medicine.
authors.forename: Alanna Chait
authors.initials: AC
authors.lastname: Mermelstein
authors.affiliation: Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Maxwell M
authors.initials: MM
authors.lastname: Chait
keywords: dexlansoprazole; erosive esophagitis; gastroesophageal reflux disease; proton pump inhibitors